Headline
The latest stories from AHA Today.
The International Code Council has named Jonathan Flannery, senior associate director of advocacy for the AHA’s American Society for Health Care Engineering, to a three-year term on the International Fire Code Development Committee, which evaluates and recommends proposed changes to the IFC fire…
Medicaid managed care organizations with enrollees dually eligible for Medicare can participate in the Direct Contracting Model’s Professional and Global Options beginning in January 2022, the Centers for Medicare & Medicaid Services announced.
Sens. Sherrod Brown, D-Ohio, and John Thune, R-S.D., introduced the Improving Seniors' Tmely Access to Care Act (S. 5044), bipartisan legislation that would require Medicare Advantage plans to establish an electronic prior authorization system and provide “real-time” decisions for routine services…
The Centers for Medicare & Medicaid Services said that will audit a sample of hospitals in January for compliance with the agency’s hospital price transparency rule that takes effect Jan. 1, 2021.
The Centers for Medicare & Medicaid Services has extended to Feb. 1 at 8 p.m. ET the deadline for clinicians participating in the Merit-based Incentive Payment System to apply for an extreme and uncontrollable circumstances exception to reweight the MIPS performance categories.
Centers for Medicare & Medicaid Services released updated guidance for states and territories on Medicaid, Children’s Health Insurance Program and Basic Health Program coverage and reimbursement for COVID-19 vaccinations.
In an article published in JAMA, Jonathan Perlin M.D., president, clinical operations, and chief medical officer, HCA Healthcare, discusses how with the COVID-19 pandemic, “the less appreciated ravage has been excess morbidity and mortality from patients who have forgone essential care due to…
The American Medical Association announced Current Procedural Terminology immunization and administration codes for reporting on medical claims the COVID-19 vaccine under development by AstraZeneca and University of Oxford.
The National Institutes of Health announced enrollment in phase 3 of the clinical trial of two disparate therapies. This trial is specifically looking at the safety and effectiveness of the therapeutics in people hospitalized with moderate COVID-19 symptoms.
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Dec. 17 recommended the approval of Moderna’s mRNA-1273 COVID-19 vaccine candidate.